Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview

Tang KWK, Millar BC, Moore JE. Antimicrobial resistance (AMR). Br J Biomed Sci. 2023;80:11387. https://doi.org/10.3389/bjbs.2023.11387 PMID:37448857 DOI: https://doi.org/10.3389/bjbs.2023.11387

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID:21793988 DOI: https://doi.org/10.1111/j.1469-0691.2011.03570.x

Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10)(suppl 2):S165-S193. https://doi.org/10.1016/j.ajic.2007.10.006 PMID:18068814 DOI: https://doi.org/10.1016/j.ajic.2007.10.006

Ancillotti M, Nihlén Fahlquist J, Eriksson S. Individual moral responsibility for antibiotic resistance. Bioethics. 2022;36(1):3-9. https://doi.org/10.1111/bioe.12958 PMID:34599841 DOI: https://doi.org/10.1111/bioe.12958

Glasner C, Berends MS, Becker K, et al. A prospective multicentre screening study on multidrug-resistant organisms in intensive care units in the Dutch-German cross-border region, 2017 to 2018: the importance of healthcare structures. Euro Surveill. 2022;27(5):1. https://doi.org/10.2807/1560-7917.ES.2022.27.5.2001660 PMID:35115078 DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.5.2001660

Murray CJL, Ikuta KS, Sharara F, et al; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. https://doi.org/10.1016/S0140-6736(21)02724-0 PMID:35065702 DOI: https://doi.org/10.1016/S0140-6736(21)02724-0

ECDC and EMEA Joint Working Group. ECDC/EMEA Joint Technical Report. The bacterial challenge: time to react. 2009. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.

European Centre for Disease Prevention and Control, Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2018, Publications Office of the European Union, 2019, https://data.europa.eu/doi/10.2900/22212. Accessed April 2024.

Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20(10):973-980. https://doi.org/10.1111/1469-0691.12798 PMID:25273968 DOI: https://doi.org/10.1111/1469-0691.12798

Iacchini S, Boros S, Pezzotti P e il gruppo di lavoro AR-ISS. AR-ISS: sorveglianza nazionale dell’Antibiotico-Resistenza. Dati 2022. Roma: Istituto Superiore di Sanità; 2023. (Rapporti ISS Sorveglianza RIS-4/2023). https://www.iss.it/documents/20126/6703853/RIS-4_2023.pdf/5a1c5341-4fe3-6a10-9a71-531a1fc829b3?t=1700464310096. Accessed April 2024.

Cassini A, Högberg LD, Plachouras D, et al; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. PMID:30409683 https://doi.org/10.1016/S1473-3099(18)30605-4 PMID:30409683 DOI: https://doi.org/10.1016/S1473-3099(18)30605-4

Italian Health Ministry. Antibiotico-resistenza nel settore umano. Aggiornamento 24/11/23. https://www.salute.gov.it/portale/antibioticoresistenza/dettaglioContenutiAntibioticoResistenza.jsp?id=5282&area=antibiotico-resistenza&menu=vuoto&tab=1. Accessed April 2024.

Suetens C, Latour K, Kärki T, et al; Healthcare-Associated Infections Prevalence Study Group. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46):1800516. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516 PMID:30458912 DOI: https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516

Moretto F, Sixt T, Devilliers H, et al. Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19? Int J Infect Dis. 2021;105:256-260. https://doi.org/10.1016/j.ijid.2021.01.051 PMID:33508478 DOI: https://doi.org/10.1016/j.ijid.2021.01.051

Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520-531. https://doi.org/10.1016/j.cmi.2020.12.018 PMID:33418017 DOI: https://doi.org/10.1016/j.cmi.2020.12.018

Bardi T, Pintado V, Gomez-Rojo M, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. 2021;40(3):495-502. https://doi.org/10.1007/s10096-020-04142-w PMID:33389263 DOI: https://doi.org/10.1007/s10096-020-04142-w

Agenzia Italiana del Farmaco (AIFA). L’uso dei farmaci in Italia. Rapporto Rappporto OsMed 2022. Published August 7, 2023. https://www.aifa.gov.it/-/l-uso-dei-farmaci-in-italia-rapporto-osmed-2022. Accessed April 2024.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. J Antimicrob Chemother. 2018;73(10):2748-2756. https://doi.org/10.1093/jac/dky235 PMID:29982565 DOI: https://doi.org/10.1093/jac/dky235

Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob Agents Chemother. 2003;47(6):1968-1971. https://doi.org/10.1128/AAC.47.6.1968-1971.2003 PMID:12760876 DOI: https://doi.org/10.1128/AAC.47.6.1968-1971.2003

Soriano A, Rossolini GM, Pea F. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Expert Rev Anti Infect Ther. 2020;18(5):415-422. https://doi.org/10.1080/14787210.2020.1746643 PMID:32223465 DOI: https://doi.org/10.1080/14787210.2020.1746643

Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical pharmacokinetics and pharmacodynamics of dalbavancin. Clin Pharmacokinet. 2022;61(3):363-374. https://doi.org/10.1007/s40262-021-01088-w PMID:34931283 DOI: https://doi.org/10.1007/s40262-021-01088-w

Cojutti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2023;65(5):e02260-20. https://doi.org/10.1128/AAC.02260-20 PMID:33649108 DOI: https://doi.org/10.1128/AAC.02260-20

Morata L, Cobo J, Fernández-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5):e02280-18. https://doi.org/10.1128/AAC.02280-18 PMID:30858217 DOI: https://doi.org/10.1128/AAC.02280-18

Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis. 2005;40(3):374-380. https://doi.org/10.1086/427283 PMID:15668859 DOI: https://doi.org/10.1086/427283

Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by Gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30. https://doi.org/10.1186/s12941-019-0329-6 PMID:31629409 DOI: https://doi.org/10.1186/s12941-019-0329-6

Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious Gram-positive infections: a review. Pharmacotherapy. 2020;40(5):469-478. https://doi.org/10.1002/phar.2389 PMID:32239771 DOI: https://doi.org/10.1002/phar.2389

Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018;67(5):795-798. https://doi.org/10.1093/cid/ciy279 PMID:29659732 DOI: https://doi.org/10.1093/cid/ciy279

Keyloun KR, Lofgren E, Hebert S. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department. J Med Econ. 2019;22(7):652-661. https://doi.org/10.1080/13696998.2019.1591423 PMID:30838908 DOI: https://doi.org/10.1080/13696998.2019.1591423

Marcellusi A, Bini C, Rotundo MA, Cultrera R, Mennini FS. Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia. Glob Reg Health Technol Assess. 2020;7(1):92-100. https://doi.org/10.33393/grhta.2020.2138 PMID:36627961 DOI: https://doi.org/10.33393/grhta.2020.2138

Oliva A, Carbonara S, Cianci V, et al. Direct or early discharge of acute bacterial skin and skin structure infection patients from the emergency department/unit: place in therapy of dalbavancin. Expert Rev Anti Infect Ther. 2023;21(7):703-721. PMID:37227028 https://doi.org/10.1080/14787210.2023.2214727 PMID:37227028 DOI: https://doi.org/10.1080/14787210.2023.2214727

Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different Gram-positive bacterial infections. Clin Drug Investig. 2021;41(5):437-448. https://doi.org/10.1007/s40261-021-01028-3 PMID:33884583 DOI: https://doi.org/10.1007/s40261-021-01028-3

Pascale R, Maccaro A, Mikus E, et al. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study. J Glob Antimicrob Resist. 2022;30:390-394. PMID:35878780 https://doi.org/10.1016/j.jgar.2022.07.018 PMID:35878780 DOI: https://doi.org/10.1016/j.jgar.2022.07.018

Eells SJ, Nguyen M, Jung J, Macias-Gil R, May L, Miller LG. Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections. Antimicrob Agents Chemother. 2016;60(5):2941-2948. PMID:26926634 https://doi.org/10.1128/AAC.02626-15 PMID:26926634 DOI: https://doi.org/10.1128/AAC.02626-15

Crapis, M., Venturini, S., Callegari et al. Usefulness of dalbavacin in early discharge and non-hospitalisation and ER experience. It’s time to throw your heart over the obstacle?. Glob Reg Health Technol Assess 2024; 11. DOI 10.33393/grhta.2024.3071.

Carbonara S. The efficacy of Dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI. Glob Reg Health Technol Assess 2024; 11. DOI 10.33393/grhta.2024.3045.